Comparative review of imipenem/cilastatin versus meropenem

  • Med Mal Infect. 2020 Jun;50(4):316-322. doi: 10.1016/j.medmal.2020.01.001.
A Salmon-Rousseau  1 ,  C Martins  2 ,  M Blot  2 ,  M Buisson  2 ,  S Mahy  2 ,  P Chavanet  2 ,  L Piroth  2
Affiliations
  • 1. Département d'Infectiologie CHU Dijon, 5, boulevard Jeanne-d'Arc, 21000 Dijon. Electronic address: [email protected].
  • 2. Département d'Infectiologie CHU Dijon, 5, boulevard Jeanne-d'Arc, 21000 Dijon.
PMID: 32035719 DOI: 10.1016/j.medmal.2020.01.001
Abstract

Introduction: Carbapenems are broad-spectrum Antibacterial molecules. Imipenem-cilastatin and meropenem are the two main molecules used in French healthcare services.

Objective: We aimed to evaluate the relative strengths and weaknesses of these two molecules by considering their pharmacokinetic, pharmacodynamic, microbiological, and clinical properties. We demonstrated that imipenem-cilastatin and meropenem are not alike.

Method: Review of the literature by querying the MEDLINE network.

Results: Imipenem-cilastatin is the first marketed molecule of the carbapenem class. It is more effective against Gram-positive cocci. Its stability does not allow for long infusions and its main adverse effect on the central nervous system limits its use. Meropenem is more effective against Gram-negative bacilli. Its stability and its milder adverse effects distinguish it from imipenem-cilastatin.

Conclusion: Meropenem is preferred for daily use in healthcare services when carbapenems are to be used.

Keywords
Antibiotic stewardship; Carbapenem; Imipenem/cilastatin; Meropenem.
Products